| Abstract | Six female patients with a primary hyperlipoproteinemia type IIa received 40 mg/day etiroxate for 2 months. Serum lipids, low density and high density lipoprotein cholesterol, the apolipoproteins B and A-I, and cholesterol and apolipoprotein A-I in ultracentrifuged HDL2 and HDL3 were analysed before and after the treatment. Etiroxate caused a significant reduction in serum cholesterol, LDL-cholesterol, and serum apolipoprotein B. Concerning the HDL, there was a significant decrease in HDL-cholesterol. The analysis of HDL subfractions revealed a uniform fall in HDL2-cholesterol and HDL2-apolipoprotein A-I. It is concluded that detailed information about lipoproteins leads to a better understanding of the relationships between drug treatment and the possible prevention of atherosclerotic diseases. |
| Authors | P Weisweiler, P Schwandt |
| Journal | Atherosclerosis
(Atherosclerosis)
Vol. 39
Issue 1
Pg. 45-9
(Apr 1981)
ISSN: 0021-9150 NETHERLANDS |
| PMID | 7247989
(Publication Type: Journal Article)
|
| Chemical References |
- Apolipoproteins
- Lipoproteins, HDL
- Lipoproteins, LDL
- Triglycerides
- etiroxate
- Cholesterol
- Thyroxine
|
| Topics |
- Adult
- Apolipoproteins
(blood)
- Cholesterol
(blood)
- Female
- Humans
- Hyperlipoproteinemia Type II
(blood, drug therapy)
- Lipoproteins, HDL
(blood)
- Lipoproteins, LDL
(blood)
- Middle Aged
- Thyroxine
(analogs & derivatives, therapeutic use)
- Triglycerides
(blood)
|
